Experienced in Sickle Cell Disease

Dr. Mercedes Porosnicu

Hematology | Oncology
Wake Forest University Health Sciences
Medical Ctr Blvd, 
Winston Salem, NC 
Accepting New Patients
Experienced in Sickle Cell Disease
Wake Forest University Health Sciences
Medical Ctr Blvd, 
Winston Salem, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mercedes Porosnicu is a Hematologist and an Oncologist in Winston Salem, North Carolina. Dr. Porosnicu is rated as an Experienced provider by MediFind in the treatment of Sickle Cell Disease. Her top areas of expertise are Adenoid Cystic Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Bone Marrow Aspiration, and Gamma Knife Radiosurgery. Dr. Porosnicu is currently accepting new patients.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
North Carolina Baptist Hospital
Languages Spoken
English
Romanian
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

WAKE FOREST UNIVERSITY HEALTH SCIENCES
Medical Ctr Blvd, Winston Salem, NC 27157
Other Locations
WAKE FOREST UNIVERSITY HEALTH SCIENCES
2311 Lewisville Clemmons Rd, Clemmons, NC 27012
WAKE FOREST UNIVERSITY HEALTH SCIENCES
2341 Lewisville Clemmons Rd, Clemmons, NC 27012

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer
Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery
Enrollment Status: Terminated
Publish Date: March 17, 2025
Intervention Type: Biological, Other, Procedure
Study Drug: Durvalumab
Study Phase: Early Phase 1
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without Chemotherapy
Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without Chemotherapy
Enrollment Status: Terminated
Publish Date: March 22, 2023
Intervention Type: Other, Drug
Study Drugs: Bupropion Hydrochloride, Nicotine Replacement, Varenicline
Study Phase: Early Phase 1
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome and on the Degree of Mucositis Developed in Response to Concurrent Chemotherapy and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome and on the Degree of Mucositis Developed in Response to Concurrent Chemotherapy and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Withdrawn
Publish Date: December 19, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

34 Total Publications

Mutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma.
Mutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma.
Journal: Cancers
Published: February 03, 2025
Similar Doctors
Advanced in Sickle Cell Disease
Dr. Andrew M. Farland
Hematology Oncology | Hematology | Oncology
Advanced in Sickle Cell Disease
Dr. Andrew M. Farland
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

2341 Lewisville Clemmons Rd, 
Clemmons, NC 
 (7.3 miles away)
336-716-2255
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Farland is a Hematologist Oncology specialist and a Hematologist in Clemmons, North Carolina. Dr. Farland is rated as a Distinguished provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Thrombotic Thrombocytopenic Purpura, Hemophilia A, Thrombocytopenia, Sickle Cell Disease, and Bone Marrow Aspiration. Dr. Farland is currently accepting new patients.

Pierre L. Triozzi
Advanced in Sickle Cell Disease
Dr. Pierre L. Triozzi
Hematology Oncology | Hematology | Oncology
Advanced in Sickle Cell Disease
Dr. Pierre L. Triozzi
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pierre Triozzi is a Hematologist Oncology specialist and a Hematologist in Winston Salem, North Carolina. Dr. Triozzi is rated as a Distinguished provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Melanoma, Melanoma of the Eye, Uveal Melanoma, Bone Marrow Aspiration, and Gastrostomy. Dr. Triozzi is currently accepting new patients.

Advanced in Sickle Cell Disease
David M. Leedy, PA
Physician Assistant | Hematology
Advanced in Sickle Cell Disease
David M. Leedy, PA
Physician Assistant | Hematology
Medical Center Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-716-2255
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Leedy is a Physician Assistant and a Hematologist in Winston Salem, North Carolina. Mr. Leedy is rated as an Advanced provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Hemoglobin SC Disease, Sickle Cell Disease, Hemoglobin E Disease, and Hemoglobinopathy. Mr. Leedy is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Porosnicu's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile